Effect of the selective serotonin reuptake inhibitors over coagulation in patients with depressive disorders – a systematic review and retrospective analysis
Journal Title: Revista de Medicină Militară - Year 2019, Vol 0, Issue 2
Abstract
Several problems related to coagulation dysfunctions induced by selective serotonin reuptake inhibitors (SSRIs) were reported in literature, as serotonin is widely distributed in the human organism and it has significant contribution in various vascular and hematologic regulatory mechanisms. First, a systematic review has integrated main results from the field of SSRIs and anticoagulants pharmacologic interactions. Secondly, a retrospective analysis was performed, based on the medical charts of hospitalized patients diagnosed with SSRI-treated depressive disorders, who also received concomitant anticoagulant treatment with acenocoumarol. Platelet count, prothrombin time, activated partial thromboplastin time, and bleeding time were monitored during hospitalization and their values before and after SSRI initiation treatment were compared.
Authors and Affiliations
Octavian Vasiliu
Keywords
Related Articles
- EP ID EP610462
- DOI -
- Views 100
- Downloads 0
Culprits in non-celiac gluten-sensitivity
-
Clostridium difficile – an emerging plague
Introduction: Clostridium difficile infection stands nowadays as one of the major emerging health problems still underestimated. Only in 2009 the European Society of Clinical Microbiology and Infection (ESCMID) was able...
Management of burning mouth syndrome (BMS) in patients with diabetes mellitus
Unlike the therapy of primary BMS, the treatment of secondary BMS benefits, in addition to symptomatic therapy, from the possibility of using means and methods to correct biological disturbances and/or morphological, psy...
Management of infectious complications in diabetes mellitus patients
Diabetes mellitus is a serious condition, causing multiple health problems due to the disease itself, but also to the complications that these patients are predisposed to. Being a current health problem, many patients te...
SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?
Two major trials, EMPA-REG OUTCOME trial (with Empagliflozin) and CANVAS trial (with Canagliflozin) have demonstrated the beneficial effects of SGLT2 inhibitors in patients with type 2 diabetes at risk for heart failure....